• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRXP; NRXPW Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: March 21, 2022

By: Bronstein, Gewirtz & Grossman, LLC via Business Wire
February 01, 2022 at 10:00 AM EST

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP; NRXPW) on behalf of purchasers of NRx securities between June 1, 2021 and November 4, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/nrxp.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies, and made false and/or misleading statements and/or failed to disclose that: (1) the ZYESAMI EUA Application contained insufficient data regarding the potential benefits and risks of ZYESAMI; (2) accordingly, the FDA was unlikely to approve the ZYESAMI EUA Application in its present form; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/nrxp or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in NRx you have until March 21, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005010/en/

Contacts

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

More News

View More
FICO’s Big Dip Could Be the Best Buying Chance of the Year
October 13, 2025
Via MarketBeat
Tickers EFX FICO
D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
October 13, 2025
Via MarketBeat
Tickers QBTS RGTI
Datavault: A Speculative AI Play, But Beware of Volatility
October 13, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Traders Are Piling Into Suncor Call Options—Should You?
October 13, 2025
Via MarketBeat
Topics World Trade
Tickers SU
Delta Air Lines Stock Looks Ready to Fly to New Highs
October 13, 2025
Via MarketBeat
Tickers DAL
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+0.00 (0.00%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap